MolDX: Plasma-Based Genomic Profiling in Solid Tumors

Plasma-based NGS (Guardant360) is covered only for patients with recurrent/relapsed/refractory/metastatic or advanced solid tumors not originating in the CNS, when tissue CGP is infeasible or (for NSCLC) tissue CGP shows no actionable mutations, and when results would inform FDA‑approved or NCCN 1/2A‑recommended biomarker-directed therapy. Prior Guardant360 testing for the same genetic content precludes repeat testing unless there is clinical evidence of tumor evolution or testing for different genetic content; other liquid biopsies may be covered if they demonstrate equivalent performance to Guardant360.

"Patient with a recurrent, relapsed, refractory, metastatic, or advanced solid tumor that did not originate from the central nervous system."

Sign up to see full coverage criteria, indications, and limitations.